Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Anbio Biotechnology changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 8 | 12 | +4 |
| Shares | 50.2K | 71.9K | +21.6K (+43.1%) |
| Value | $1.29M | $985.2K | −$305.2K (−23.6%) |
New holders (6)
Institutions that held Anbio Biotechnology at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of America Corp | 13,419 | $184.0K | 0.00% |
| Marshall Wace, LLP | 11,502 | $157.7K | 0.00% |
| Advisor Group Holdings, Inc. | 77 | $1.06K | 0.00% |
| JPMorgan Chase & Co | 53 | $718 | 0.00% |
| Larson Financial Group LLC | 5 | $69 | 0.00% |
| Silver Grove Financial Group, Inc. | 4 | $55 | 0.00% |
Sold out (2)
Institutions that held Anbio Biotechnology at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Wells Fargo & Company | 100 | $2.57K |
| Ronald Blue Trust, Inc. | 5 | $128 |